Aurobindo Pharma falls 7% on receiving warning letter from USFDA for Srikakulam facility
Updated : June 21, 2019 11:29 AM IST
The stock fell as much as 7.6 percent to Rs 578.75 per share on the BSE in the opening trade.
The company received a warning letter from the US FDA for Srikakulam facility after the February inspection.
The stock has fallen 12 percent in the last one month and 20 percent in 2019.
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more